| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 27, 2003
From the Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pa. * To whom correspondence should be addressed. E-mail: menegazz+{at}pitt.edu.
Background--The scaling exponent (ScE) of the ventricular fibrillation (VF) waveform correlates with duration of VF and predicts defibrillation outcome. We compared 4 therapeutic approaches to the treatment of VF of various durations. Methods and Results--Seventy-two swine (19.5 to 25.7 kg) were randomly assigned to 1 of 9 groups (n=8 each). VF was induced and left untreated until the ScE reached 1.10, 1.20, 1.30, or 1.40. Animals were treated with either immediate countershock (IC); 3 minutes of CPR before the first countershock (CPR); CPR for 2 minutes, then drugs given with 3 more minutes of CPR before the first shock (CPR-D); or drugs given at the start of CPR with 3 minutes of CPR before the first shock (Drugs+CPR). Return of spontaneous circulation (ROSC) and 1-hour survival were analyzed with Conclusions--VF of brief to moderate duration is effectively treated by IC. When VF is prolonged, as indicated by an ScE of 1.3 or greater, IC was not effective and delayed time to ROSC. The ScE can help in choosing the first intervention in the treatment of VF.
Revised on October 13, 2003
Accepted on October 14, 2003
Ventricular Fibrillation Scaling Exponent Can Guide Timing of Defibrillation and Other Therapies
James J. Menegazzi PhD*,
2 and Kaplan-Meier survival curves. IC was effective when the ScE was low but had decreasing success as the ScE increased. No animals in the 1.30 or 1.40 groups had ROSC from IC (0 of 16). CPR did not improve first shock outcome in the 1.20 CPR group (3 of 8 ROSC). Kaplan-Meier survival analyses indicated that IC significantly delayed time to ROSC in both the 1.3 (P=0.0006) and the 1.4 (P=0.005) groups.
This article has been cited by other articles:
![]() |
N. A. Lever, E. G. Newall, and P. D. Larsen Differences in the characteristics of induced and spontaneous episodes of ventricular fibrillation Europace, November 1, 2007; 9(11): 1054 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Huizar, M. D. Warren, A. G. Shvedko, J. Kalifa, J. Moreno, S. Mironov, J. Jalife, and A. V. Zaitsev Three distinct phases of VF during global ischemia in the isolated blood-perfused pig heart Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1617 - H1628. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-q. Zhong, G. Laurent, P. P.-S. So, Xudong Hu, J. K. Hennan, and P. Dorian Effects of Rotigaptide, a Gap Junction Modifier, on Defibrillation Energy and Resuscitation From Cardiac Arrest in Rabbits Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 69 - 77. [Abstract] [PDF] |
||||
![]() |
Part 5: Electrical Therapies: Automated External Defibrillators, Defibrillation, Cardioversion, and Pacing Circulation, December 13, 2005; 112(24_suppl): IV-35 - IV-46. [Full Text] [PDF] |
||||
![]() |
K. A. Marill and P. T. Ellinor Case 37-2005 -- A 35-Year-Old Man with Cardiac Arrest while Sleeping N. Engl. J. Med., December 8, 2005; 353(23): 2492 - 2501. [Full Text] [PDF] |
||||
![]() |
Part 3: Defibrillation Circulation, November 29, 2005; 112(22_suppl): III-17 - III-24. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |